Chesapeake IRB Announces Acquisition of MaGil IRB
Columbia, Md., June 7, 2017 (Business Wire) – Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced it has acquired MaGil IRB, a central IRB located in Rockville, Md.
The MaGil acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and a staff that broadens Chesapeake’s presence for CROs, pharmaceutical companies, and biotech companies. This marks Chesapeake’s fifth acquisition of an AAHRPP-accredited IRB since 2013, further positioning itself as an IRB to support the growth in the clinical research industry.
“Today we are delighted to welcome MaGil IRB to the Chesapeake family,” said Jeff Wendel, president and CEO of Chesapeake. “Together, we are even better positioned to deliver unparalleled human subject protections and oversight and exceptional client service.”
“Joining with Chesapeake allows MaGil customers to benefit from Chesapeake’s innovative cloud-based IRB platform, CIRBI, while continuing the joint mission of safeguarding the rights and welfare of clinical research participants,” said Gil Price, co-founder and CEO of MaGil IRB.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit chesapeakeirb.com for more information.
CONTACT:
Lea Studer
SCORR Marketing
308.237.5567
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
